Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models

A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises... Oncol Ther (2016) 4:257–274 DOI 10.1007/s40487-016-0031-1 ORIGINAL RESEARCH A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models . . . Wafaa Hassan Kenny Chitcholtan Peter Sykes Ashley Garrill Received: July 12, 2016 / Published online: September 27, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com EGFR/Her-2 inhibitor (canertinib) and a c-Met ABSTRACT inhibitor (PHA665752) in ovarian cancer cell Introduction: Advanced ovarian cancer is often lines in 3D cell aggregates. a fatal disease as chemotherapeutic drugs have Methods: OVCAR-5 and SKOV-3 ovarian cancer limited effectiveness. Better targeted therapy is cell lines were cultured on a non-adherent needed to improve the survival and quality of surface to produce 3D cell clusters and life for these women. Receptor tyrosine kinases aggregates. Cells were exposed to canertinib including EGFR, Her-2 and c-Met are associated and PHA665752, both individually and in with a poor prognosis in ovarian cancer. combination, for 48 h. The effect on growth, Therefore, the co-activation of these receptors metabolism and the expression/ may be crucial for growth promoting activity. phosphorylation of selective signaling proteins In this study, we explored the effect of associated with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models

Loading next page...
 
/lp/springer-journals/a-combination-of-two-receptor-tyrosine-kinase-inhibitors-canertinib-iGxX4SBIPP
Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-016-0031-1
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2016) 4:257–274 DOI 10.1007/s40487-016-0031-1 ORIGINAL RESEARCH A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models . . . Wafaa Hassan Kenny Chitcholtan Peter Sykes Ashley Garrill Received: July 12, 2016 / Published online: September 27, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com EGFR/Her-2 inhibitor (canertinib) and a c-Met ABSTRACT inhibitor (PHA665752) in ovarian cancer cell Introduction: Advanced ovarian cancer is often lines in 3D cell aggregates. a fatal disease as chemotherapeutic drugs have Methods: OVCAR-5 and SKOV-3 ovarian cancer limited effectiveness. Better targeted therapy is cell lines were cultured on a non-adherent needed to improve the survival and quality of surface to produce 3D cell clusters and life for these women. Receptor tyrosine kinases aggregates. Cells were exposed to canertinib including EGFR, Her-2 and c-Met are associated and PHA665752, both individually and in with a poor prognosis in ovarian cancer. combination, for 48 h. The effect on growth, Therefore, the co-activation of these receptors metabolism and the expression/ may be crucial for growth promoting activity. phosphorylation of selective signaling proteins In this study, we explored the effect of associated with

Journal

Oncology and TherapySpringer Journals

Published: Sep 27, 2016

References